• Expression of Mitochondrial Cytochrome C Oxidase Chaperone Gene (COX20) Improves Tolerance to Weak Acid and Oxidative Stress during Yeast Fermentation. 

  Kumar, V; Hart, AJ; Keerthiraju, ER; Waldron, PR; Tucker, GA; et al. (PUBLIC LIBRARY SCIENCE, 2015-10-01)

  INTRODUCTION: Saccharomyces cerevisiae is the micro-organism of choice for the conversion of fermentable sugars released by the pre-treatment of lignocellulosic material into bioethanol. Pre-treatment of lignocellulosic ...
• Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. 

  Yap, TA; Winter, JN; Giulino-Roth, L; Longley, J; Lopez, J; et al. (AMER ASSOC CANCER RESEARCH, 2019-12-15)

  PURPOSE: Enhancer of zeste homolog 2 (EZH2) activity is dysregulated in many cancers. PATIENTS AND METHODS: This phase I study determined the safety, maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of ...
• Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. 

  Kristeleit, R; Evans, J; Molife, LR; Tunariu, N; Shaw, H; et al. (SPRINGERNATURE, 2020-08-03)

  BACKGROUND: BAL101553 (lisavanbulin), the lysine prodrug of BAL27862 (avanbulin), exhibits broad anti-proliferative activity in human cancer models refractory to clinically relevant microtubule-targeting agents. METHODS: ...
• First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. 

  Falchook, G; Infante, J; Arkenau, H-T; Patel, MR; Dean, E; et al. (ELSEVIER, 2021-04-01)

  BACKGROUND: We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane. ...
• Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. 

  Yap, TA; Krebs, MG; Postel-Vinay, S; El-Khouiery, A; Soria, J-C; et al. (AMER ASSOC CANCER RESEARCH, 2021-10-01)

  PURPOSE: This study reports the safety, tolerability, MTD, recommended phase II dose (RP2D), pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of ceralasertib combined with carboplatin in patients ...

View more